Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia H Hayes

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
JAMA|March 20, 2014
Screening for prostate cancer with the prostate-specific antigen test: a review of current evidenceJulia H Hayes, Michael J Barry
JAMA|November 18, 2015
Evaluating an Elevated Screening PSA TestMichael J Barry, Julia H Hayes
Cancer|October 12, 2013
Reply to clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal diseaseJulia H Hayes, Mari Nakabayashi, Philip W Kantoff
Annals of Internal Medicine|October 16, 2013
Observation versus initial treatment for prostate cancerJulia H Hayes, Michael J Barry, Pamela M McMahon
BJU International|August 3, 2007
Prostate-specific antigen screening for prostate cancer: a decision-analytical perspectiveJulia H Hayes, Michael J Barry, Philip W Kantoff, et al.
Clinical Genitourinary Cancer|July 5, 2011
Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantationDarryl B Sneag, Nikhil Ramaiya, Kevin N O'Regan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cellsMasahito Shimizu, Masumi Suzui, Atsuko Deguchi, et al.
Annals of Internal Medicine|June 20, 2013
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysisJulia H Hayes, Daniel A Ollendorf, Steven D Pearson, et al.
Cancer|April 24, 2015
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancerRana R McKay, Kathryn P Gray, Julia H Hayes, et al.
BJU International|March 17, 2010
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or strokeJulia H Hayes, Ming-Hui Chen, Brian J Moran, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
JAMA|March 20, 2014
Screening for prostate cancer with the prostate-specific antigen test: a review of current evidenceJulia H Hayes, Michael J Barry
JAMA|November 18, 2015
Evaluating an Elevated Screening PSA TestMichael J Barry, Julia H Hayes
Cancer|October 12, 2013
Reply to clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal diseaseJulia H Hayes, Mari Nakabayashi, Philip W Kantoff
Annals of Internal Medicine|October 16, 2013
Observation versus initial treatment for prostate cancerJulia H Hayes, Michael J Barry, Pamela M McMahon
BJU International|August 3, 2007
Prostate-specific antigen screening for prostate cancer: a decision-analytical perspectiveJulia H Hayes, Michael J Barry, Philip W Kantoff, et al.
Clinical Genitourinary Cancer|July 5, 2011
Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantationDarryl B Sneag, Nikhil Ramaiya, Kevin N O'Regan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cellsMasahito Shimizu, Masumi Suzui, Atsuko Deguchi, et al.
Annals of Internal Medicine|June 20, 2013
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysisJulia H Hayes, Daniel A Ollendorf, Steven D Pearson, et al.
Cancer|April 24, 2015
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancerRana R McKay, Kathryn P Gray, Julia H Hayes, et al.
BJU International|March 17, 2010
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or strokeJulia H Hayes, Ming-Hui Chen, Brian J Moran, et al.
Pageof 2